Article Text

OP0006 Eular evidence-based recommendations on the management of medium to high dose systemic glucocorticoid therapy in rheumatic diseases
  1. N. Duru1,
  2. M.C. van der Goes1,
  3. J.W. Jacobs1,
  4. T. Andrews2,
  5. M. Boers3,
  6. F. Buttgereit4,
  7. N. Caeyers5,
  8. M. Cutolo6,
  9. S. Halliday2,
  10. J.A. da Silva7,
  11. J.R. Kirwan8,
  12. D. Ray9,
  13. J. Rovensky10,
  14. G. Severijns5,
  15. R. Westhovens11,
  16. J.W. Bijlsma1
  1. 1Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht, Netherlands
  2. 2EULAR Social Leagues, Patients’ Representative, Bristol, United Kingdom
  3. 3Clinical Epidemiology and Biostatistics, VU University Medical Centre, Amsterdam, Netherlands
  4. 4Rheumatology and Clinical Immunology, Charité Universitätsmedizin Berlin, Berlin, Germany
  5. 5EULAR Social Leagues, Patients’ Representative, Leuven, Belgium
  6. 6Research Laboratory and Division of Rheumatology, Department of Internal Medicine, University of Genova, Genova, Italy
  7. 7Reumatologia, Hospitais da Universidade de Coimbra, Coimbra, Portugal
  8. 8University of Bristol Academic Rheumatology Unit, Bristol Royal Infirmary, Bristol
  9. 9Department of Endocrinology & Diabetes Group, Developmental Biomedicine Research Group, University of Manchester, Manchester, United Kingdom
  10. 10National Institute of Rheumatic Diseases, Piest’any, Slovakia
  11. 11Rheumatology, University Hospitals KU Leuven, Leuven, Belgium


Objectives To develop recommendations for the management of medium to high dose systemic glucocorticoid (GC) therapy in rheumatic diseases.

Methods A multidisciplinary EULAR task force was formed, comprising of 8 rheumatologists, 1 endocrinologist, 1 rheumatologist–epidemiologist, 4 patients and 2 research fellows from 7 European countries. Each participant contributed 10 propositions describing key clinical points concerning the safe use of medium to high dose GCs. The final recommendations were developed using a Delphi consensus approach and the wording was improved by a native speaker. A systematic literature search of PUBMED, EMBASE and Cochrane Library was used to identify the best available research evidence to support each of the propositions. The strength of recommendation was given according to research evidence, clinical expertise and patient preference.

Results The 10 final propositions included the topics patient education and informing general practitioners, preventive measures for osteoporosis, optimal GC starting dosages, risk-benefit ratio of GC treatment, GC sparing therapy, screening for co morbidity, and monitoring for adverse events. Most of the propositions were only indirectly supported by evidence from literature. The strength of each recommendation differed according to the level of evidence and clinical expertise, but was generally low because available literature on medium to high dose GC therapy was limited.

Conclusions Ten recommendations for the management of medium to high dose systemic GC therapy in rheumatic diseases were formulated, and strengths of recommendation were provided. Robust evidence was often lacking and items in need for further research were defined.

Disclosure of Interest None Declared

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.